<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273661</url>
  </required_header>
  <id_info>
    <org_study_id>NEBULAMB</org_study_id>
    <nct_id>NCT02273661</nct_id>
  </id_info>
  <brief_title>Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).</brief_title>
  <acronym>NEBULAMB</acronym>
  <official_title>Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      Compare the incidence of severe clinical exacerbations in the treatment of ABPA, between a
      strategy with a maintenance treatment and a conventional strategy without antifungal
      maintenance therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2014</start_date>
  <completion_date type="Anticipated">February 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of first severe clinical exacerbation</measure>
    <time_frame>within 24 months following the attack treatment,</time_frame>
    <description>Occurrence of severe clinical exacerbation within 24 months following attack treatment, defined by the onset or worsening of dyspnea aggravating the baseline condition that justified:
-increased inhalation treatments (inhaled bronchodilators and / or corticosteroids)
and / or initiation of systemic corticosteroid treatment
and / or hospitalization
AND persisting for more than 7 days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Allergic Bronchopulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An aerosol of isotonic saline x 1/ week will be administered during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambisome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B (Ambisome®)</intervention_name>
    <description>An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months</description>
    <arm_group_label>Ambisome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>An aerosol of isotonic saline x 1/ week will be administered during 6 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients with ABPA justifying an attack treatment with corticosteroids and itraconazole
        and combining the following criteria:

          1. atopic subject or a history of asthma , history of total Immunoglobin E (IgE)&gt; 417 kU
             / L (or &gt; 210 kU / L with a clear worsening) of a known ABPA), specific Immunoglobin E
             against Aspergillus fumigatus positive ( &gt;0.35 KUA/L) or positive skin tests.

          2. associated with two other of the following criteria: documentation of precipitating
             antibodies or Immunoglobulin G positive to Aspergillus fumigatus, of radiological
             infiltrates associated with ABPA (transitional / persistent / bronchial dilation), of
             blood eosinophilia &gt; 500 elements/mm3.

          3. After informing and obtaining consent signed.

        Exclusion Criteria:

          -  Women of childbearing age who do not have an effective contraception for at least 12
             first months of the study( 10 months + 2 months of treatment washout) pregnant or
             lactating women,

          -  Patient with cystic fibrosis

          -  Patient with a contra-indication to itraconazole

          -  Intolerance to β2 -agonists

          -  Known hypersensitivity to liposomal amphotericin B or any other component

          -  Laboratory abnormalities: significant abnormalities of platelet blood count , liver
             function tests (SGPT, SGOT(serum glutamate oxaloacetate transaminase) , total
             bilirubin &gt; 5 times the upper limit of the normal range )

          -  severe renal function impairment (creatinine clearance enf to 30 ml/min)

          -  Concomitant use of one or more of the following treatments: Alfuzosine, alcaloïdes de
             l'ergot de seigle vasoconstricteur, aliskiren, astemizole, atorvastatine, avanafil,
             association Ombitasvir and Paritaprevir, Bepridil, Cisaprid, Dabigatran, dapoxetin,
             domperidon, dronedaron, Eplerenone, Halofantrin, Ivabradin, Lomitapid, lurasidon,
             Millepertuis, mizolastin, Pimozid,Quétiapin, quinidin, Ranolazine, ritonavir,
             Sertindole, sildénafil, simvastatin, sirolimus, Sultoprid, Terfenadine, ticagrelor,
             triazolam Vardénafil (in men over than 75)

          -  patient with anti IgE- monoclonal antibody for less than 4 months or with current
             complications related to previous treatment with anti IgE- monoclonal antibody -

          -  Ventricular dysfunction demonstrated such as congestive heart failure or a history of
             congestive heart failure

          -  Simple aspergilloma, chronic pulmonary aspergillosis, invasive pulmonary aspergillosis

          -  Respiratory infection aggravating asthma or ABPA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Aspergillosis, Allergic Bronchopulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

